TY - JOUR
T1 - A case series describing the recurrence of COVID-19 in patients who recovered from initial Illness in Bangladesh
AU - Das, Pritimoy
AU - Satter, Syed M.
AU - Ross, Allen G.
AU - Abdullah, Zarin
AU - Nazneen, Arifa
AU - Sultana, Rebeca
AU - Rimi, Nadia Ali
AU - Chowdhury, Kamal
AU - Alam, Rashedul
AU - Parveen, Shahana
AU - Rahman, Md Mahfuzur
AU - Hossain, Mohammad Enayet
AU - Rahman, Mohammed Ziaur
AU - Mazumder, Razib
AU - Abdullah, Ahmed
AU - Rahman, Mahmudur
AU - Banu, Sayera
AU - Ahmed, Tahmeed
AU - Clemens, John D.
AU - Rahman, Mustafizur
N1 - Funding Information:
Funding: The case report is a part of “COVID-19 testing and tracing in Bangladesh” study funded by the Bill and Melinda Gates Foundation (Investment ID INV-017556).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/3/31
Y1 - 2021/3/31
N2 - To date, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 80 million people globally. We report a case series of five clinically and laboratory confirmed COVID-19 patients from Bangladesh who suffered a second episode of COVID-19 illness after 70 symptom-free days. The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), is a leading public health research institution in South Asia. icddr, b staff were actively tested, treated and followed-up for COVID-19 by an experienced team of clinicians, epidemiologists, and virologists. From 21 March to 30 September 2020, 1370 icddr,b employees working at either the Dhaka (urban) or Matlab (rural) clinical sites were tested for COVID-19. In total, 522 (38%) were positive; 38% from urban Dhaka (483/1261) and 36% from the rural clinical site Matlab (39/109). Five patients (60% male with a mean age of 41 years) had real-time reverse transcription-polymerase chain reaction (rRT-PCR) diagnosed recurrence (reinfection) of SARS-CoV-2. All had mild symptoms except for one who was hospitalized. Though all cases reported fair risk perceptions towards COVID-19, all had potential exposure sources for reinfection. After a second course of treatment and home isolation, all patients fully recovered. Our findings suggest the need for COVID-19 vaccination and continuing other preventive measures to further mitigate the pandemic. An optimal post-recovery follow-up strategy to allow the safe return of COVID-19 patients to the workforce may be considered.
AB - To date, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 80 million people globally. We report a case series of five clinically and laboratory confirmed COVID-19 patients from Bangladesh who suffered a second episode of COVID-19 illness after 70 symptom-free days. The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), is a leading public health research institution in South Asia. icddr, b staff were actively tested, treated and followed-up for COVID-19 by an experienced team of clinicians, epidemiologists, and virologists. From 21 March to 30 September 2020, 1370 icddr,b employees working at either the Dhaka (urban) or Matlab (rural) clinical sites were tested for COVID-19. In total, 522 (38%) were positive; 38% from urban Dhaka (483/1261) and 36% from the rural clinical site Matlab (39/109). Five patients (60% male with a mean age of 41 years) had real-time reverse transcription-polymerase chain reaction (rRT-PCR) diagnosed recurrence (reinfection) of SARS-CoV-2. All had mild symptoms except for one who was hospitalized. Though all cases reported fair risk perceptions towards COVID-19, all had potential exposure sources for reinfection. After a second course of treatment and home isolation, all patients fully recovered. Our findings suggest the need for COVID-19 vaccination and continuing other preventive measures to further mitigate the pandemic. An optimal post-recovery follow-up strategy to allow the safe return of COVID-19 patients to the workforce may be considered.
KW - Bangladesh
KW - COVID-19
KW - Recurrence
KW - Reinfection
UR - http://www.scopus.com/inward/record.url?scp=85106870836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106870836&partnerID=8YFLogxK
U2 - 10.3390/tropicalmed6020041
DO - 10.3390/tropicalmed6020041
M3 - Article
C2 - 33807247
AN - SCOPUS:85106870836
SN - 2414-6366
VL - 6
JO - Tropical Medicine and Infectious Disease
JF - Tropical Medicine and Infectious Disease
IS - 2
M1 - 41
ER -